What You Should Know:
– Medable Inc., a leader in clinical development technology, has announced Medable AI, a suite of generative AI capabilities designed to revolutionize the clinical trial startup process. Medable AI empowers sponsors and clinical research organizations (CROs) to build digital and decentralized trials faster, with greater efficiency and control.
– The launch of Medable AI is part of a broader AI strategy for Medable, with plans to expand AI capabilities across its platform in the future. This reflects the company’s commitment to leveraging cutting-edge technology to accelerate clinical development and improve patient outcomes.
Accelerating Time to First Patient In (FPI)
Medable AI, integrated into the Medable Studio platform, automates time-consuming manual tasks that traditionally slow down clinical trial startup. By streamlining processes and eliminating repetitive work, Medable AI significantly reduces the time to First Patient In (FPI).
For example, building multiple outcomes assessments for a study, a process that typically takes days, can now be completed in just 30 minutes with Medable AI, according to early metrics. This accelerated timeline represents a major breakthrough for the industry, moving towards the ambitious goal of one-day study startup.
Enhanced Efficiency and Control
Medable AI offers a range of capabilities to enhance the trial build process:
- Automated eCOA Creation: Automatically converts existing outcomes assessments into fully digital eCOAs in seconds.
- Simplified Editing: Provides a user-friendly, ChatGPT-like interface for easy editing of assessments.
- Scalable Assessment Generation: Enables the generation and scaling of assessments with varying complexity and logic.
These features provide users with greater transparency and control over trial builds, streamlining workflows and improving efficiency.
Availability
The Medable AI-integrated Studio platform is expected to be generally available in December 2024, offering sponsors and CROs a powerful new tool to accelerate clinical trials and bring innovative therapies to patients faster.
“Medable is excited to leverage AI in our mission to make clinical trials more accessible to more patients,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “We are focused on step function change – true innovation, not iteration. As fast as the world is changing, this is critical, and we are starting by taking eCOA and DCT off the critical path. This is just the beginning.”
